New research sheds light on the global burden of atopic dermatitis, the most common chronic inflammatory skin disease, affecting more than 200 million individuals worldwide.
The research, which is published in the Lancet, also takes a deep dive into novel targeted treatments for AD.
Emma Guttman-Yassky, MD, PhD Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, collaborated with Patrick Brunner, MD, MSc, of Mount Sinai and Yael Renert-Yuval, MD, MSc, of Schneider Children’s Medical Center of Israel on the article.
“It is an honor to contribute this seminar to The Lancet, which reflects Mount Sinai’s leadership in advancing dermatological science and improving patient care,” says Dr. Guttman-Yassky in a news release. “Our work provides a comprehensive understanding of the underlying mechanisms that have led to novel treatments for atopic dermatitis, with broad implications for the medical, allergy, and dermatological communities.”
Dr. Brunner adds, “We would like to stress that atopic dermatitis doesn’t just affect the skin—it can take a toll on emotional well-being and quality of life. This publication is a step forward in helping clinicians understand and treat this complex condition with the latest therapeutic advances.”
